{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:49Z","timestamp":1792785049443,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Study Abroad Program of the Ministry of National Education, The Republic of T\u00fcrkiye","award":["EABGA6ATKILK4Y8"],"award-info":[{"award-number":["EABGA6ATKILK4Y8"]}]},{"name":"Novo Nordisk Fonden","award":["NNF22SA0081890"],"award-info":[{"award-number":["NNF22SA0081890"]}],"id":[{"id":"https:\/\/ror.org\/04txyc737","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Novo Nordisk Fonden","award":["NNF22SA0081890"],"award-info":[{"award-number":["NNF22SA0081890"]}],"id":[{"id":"https:\/\/ror.org\/04txyc737","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Novo Nordisk Fonden","award":["NNF22SA0081890"],"award-info":[{"award-number":["NNF22SA0081890"]}],"id":[{"id":"https:\/\/ror.org\/04txyc737","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Canadian Institutes of Health Research (CIHR) under the Project Grant - Priority Announcement: Pandemic Preparedness and Health Emergencies Research","award":["PPE-196071"],"award-info":[{"award-number":["PPE-196071"]}],"id":[{"id":"https:\/\/ror.org\/01gavpb45","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Government of Saskatchewan","award":["Innovation Saskatchewan, Ministry of Agriculture"],"award-info":[{"award-number":["Innovation Saskatchewan, Ministry of Agriculture"]}],"id":[{"id":"https:\/\/ror.org\/04ch2gv47","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Canada Foundation for Innovation","award":["Major Science Initiatives Fund"],"award-info":[{"award-number":["Major Science Initiatives Fund"]}],"id":[{"id":"https:\/\/ror.org\/000az4664","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Danmarks Frie Forskningsfond","award":["DFF-9041-00198B"],"award-info":[{"award-number":["DFF-9041-00198B"]}],"id":[{"id":"https:\/\/ror.org\/05svhj534","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60179-5","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:26:10Z","timestamp":1783092370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Induction of mucosal immune responses against SARS-CoV-2: a heterologous intramuscular mRNA-LNP prime\/pulmonary recombinant subunit pull vaccination strategy"],"prefix":"10.1038","volume":"16","author":[{"given":"Melike","family":"Ongun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Suresh","family":"Kola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasson","family":"da Costa Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe Tandrup","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet Girish","family":"Lokras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Franzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren R.","family":"Paludan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-5588","authenticated-orcid":false,"given":"Camilla","family":"Foged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"60179_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"New. Engl. J. Med."},{"key":"60179_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423 (2021).","journal-title":"N Engl. J. Med."},{"key":"60179_CR3","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1093\/cid\/ciac106","volume":"75","author":"M Risk","year":"2022","unstructured":"Risk, M. et al. Comparative effectiveness of coronavirus disease 2019 (COVID-19) vaccines against the delta variant. Clin. Infect. Dis. 75, e623\u2013e629 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"60179_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N Engl. J. Med."},{"key":"60179_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","volume":"22","author":"A Singanayagam","year":"2022","unstructured":"Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect. Dis. 22, 183\u2013195 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"60179_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cell.2021.12.027","volume":"185","author":"KJ Siddle","year":"2022","unstructured":"Siddle, K. J. et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell 185, 485\u2013492e410 (2022).","journal-title":"Cell"},{"key":"60179_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12916-024-03444-6","volume":"22","author":"T Althaus","year":"2024","unstructured":"Althaus, T. et al. How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022. BMC Med. 22, 227 (2024).","journal-title":"BMC Med."},{"key":"60179_CR8","doi-asserted-by":"publisher","first-page":"104435","DOI":"10.1016\/j.ebiom.2022.104435","volume":"88","author":"L Azzi","year":"2023","unstructured":"Azzi, L. et al. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine. Ebiomedicine 88, 104435 (2023).","journal-title":"Ebiomedicine"},{"key":"60179_CR9","doi-asserted-by":"publisher","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","volume":"75","author":"L Azzi","year":"2022","unstructured":"Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. Ebiomedicine 75, 103788 (2022).","journal-title":"Ebiomedicine"},{"key":"60179_CR10","doi-asserted-by":"crossref","unstructured":"Loconsole, D. et al. Autochthonous outbreak of SARS-CoV-2 omicron variant in Booster-vaccinated (3 Doses) healthcare workers in Southern Italy: Just the tip of the Iceberg? Vaccines (Basel) 10 (2022).","DOI":"10.3390\/vaccines10020283"},{"key":"60179_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/22221751.2022.2053365","volume":"11","author":"JY Lam","year":"2022","unstructured":"Lam, J. Y. et al. H. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants. Emerg. Microbes Infect. 11, 964\u2013967 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"60179_CR12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/infdis\/jiae450","volume":"230","author":"Y Tang","year":"2024","unstructured":"Tang, Y. et al. COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children. J. Infect. Dis. 230, 1390\u20131399 (2024).","journal-title":"J. Infect. Dis."},{"key":"60179_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/infdis\/jiad353","volume":"228","author":"N Lasrado","year":"2023","unstructured":"Lasrado, N. & Barouch, D. H. SARS-CoV-2 hybrid immunity: The best of both worlds. J. Infect. Dis. 228, 1311\u20131313 (2023).","journal-title":"J. Infect. Dis."},{"key":"60179_CR14","doi-asserted-by":"crossref","unstructured":"Bates, T. A. et al. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. JCI Insight 8 (2023).","DOI":"10.1172\/jci.insight.165265"},{"key":"60179_CR15","doi-asserted-by":"crossref","unstructured":"Laghlali, G. et al. Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime\/intranasal protein boost vaccination with a combination adjuvant. Mol. Ther. 32 (12), 4448-4466 (2024).","DOI":"10.1016\/j.ymthe.2024.10.016"},{"key":"60179_CR16","doi-asserted-by":"publisher","first-page":"eabo2523","DOI":"10.1126\/science.abo2523","volume":"378","author":"T Mao","year":"2022","unstructured":"Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).","journal-title":"Science"},{"key":"60179_CR17","doi-asserted-by":"publisher","first-page":"eadh1655","DOI":"10.1126\/sciadv.adh1655","volume":"9","author":"G Baldeon Vaca","year":"2023","unstructured":"Baldeon Vaca, G. et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci. Adv. 9, eadh1655 (2023).","journal-title":"Sci. Adv."},{"key":"60179_CR18","doi-asserted-by":"publisher","first-page":"e0228023","DOI":"10.1128\/mbio.02280-23","volume":"14","author":"D Bhavsar","year":"2023","unstructured":"Bhavsar, D. et al. Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection. mBio 14, e0228023 (2023).","journal-title":"mBio"},{"key":"60179_CR19","doi-asserted-by":"publisher","first-page":"101668","DOI":"10.1016\/j.xcrm.2024.101668","volume":"5","author":"WN Voss","year":"2024","unstructured":"Voss, W. N. et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell. Rep. Med. 5, 101668 (2024).","journal-title":"Cell. Rep. Med."},{"key":"60179_CR20","first-page":"100134","volume":"6","author":"KJ Bruxvoort","year":"2022","unstructured":"Bruxvoort, K. J. et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg. Health Am. 6, 100134 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"60179_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2115463","volume":"386","author":"BA Dickerman","year":"2022","unstructured":"Dickerman, B. A. et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N. Engl. J. Med. 386, 105\u2013115 (2022).","journal-title":"N Engl. J. Med."},{"key":"60179_CR22","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N Engl. J. Med."},{"key":"60179_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh, E. E. et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N. Engl. J. Med. 388, 1465\u20131477 (2023).","journal-title":"N Engl. J. Med."},{"key":"60179_CR24","doi-asserted-by":"publisher","first-page":"e10060","DOI":"10.1002\/amp2.10060","volume":"2","author":"Z Kis","year":"2020","unstructured":"Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R. & Shah, N. Rapid development and deployment of high-volume vaccines for pandemic response. J. Adv. Manuf. Process. 2, e10060 (2020).","journal-title":"J. Adv. Manuf. Process."},{"key":"60179_CR25","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"60179_CR26","doi-asserted-by":"crossref","unstructured":"Wu, K. et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine 39, 7394-7400 (2021).","DOI":"10.1016\/j.vaccine.2021.11.001"},{"key":"60179_CR27","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"XC Hou","year":"2021","unstructured":"Hou, X. C., Zaks, T., Langer, R. & Dong, Y. Z. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"60179_CR28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"60179_CR29","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem., Int. Ed. Engl. 51, 8529\u20138533 (2012).","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"60179_CR30","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).","journal-title":"Nat. Commun."},{"key":"60179_CR31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.xphs.2022.12.026","volume":"112","author":"M Kawaguchi","year":"2023","unstructured":"Kawaguchi, M. et al. Effect of cholesterol content of lipid composition in mRNA-LNPs on the protein expression in the injected site and liver after local administration in mice. J. Pharm. Sci. 112, 1401\u20131410 (2023).","journal-title":"J. Pharm. Sci."},{"key":"60179_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jconrel.2022.05.020","volume":"347","author":"SK Patel","year":"2022","unstructured":"Patel, S. K. et al. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. J. Controlled Release. 347, 521\u2013532 (2022).","journal-title":"J. Control Release"},{"key":"60179_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","volume":"99","author":"X Cheng","year":"2016","unstructured":"Cheng, X. & Lee, R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Delivery Rev. 99, 129\u2013137 (2016).","journal-title":"Adv. Drug Deliv Rev."},{"key":"60179_CR34","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Delivery Rev. 188, 114416 (2022).","journal-title":"Adv. Drug Deliv Rev."},{"key":"60179_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jconrel.2004.04.026","volume":"98","author":"A Vila","year":"2004","unstructured":"Vila, A., Gill, H., McCallion, O. & Alonso, M. J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Controlled Release. 98, 231\u2013244 (2004).","journal-title":"J. Control Release"},{"key":"60179_CR36","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","volume":"34","author":"BS Schuster","year":"2013","unstructured":"Schuster, B. S., Suk, J. S., Woodworth, G. F. & Hanes, J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 34, 3439\u20133446 (2013).","journal-title":"Biomaterials"},{"key":"60179_CR37","doi-asserted-by":"crossref","unstructured":"Suberi, A. et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci. Transl. Med. 15, eabq0603 (2023).","DOI":"10.1126\/scitranslmed.abq0603"},{"key":"60179_CR38","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","volume":"32","author":"JT van Dissel","year":"2014","unstructured":"van Dissel, J. T. et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32, 7098\u20137107 (2014).","journal-title":"Vaccine"},{"key":"60179_CR39","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"60179_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41579-022-00822-w","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. 21, 147\u2013161 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"60179_CR41","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. U. S. A. 107, 1864\u20131869 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"60179_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jcis.2022.11.141","volume":"633","author":"A Aljabbari","year":"2023","unstructured":"Aljabbari, A. et al. Elucidating the nanostructure of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles. J. Colloid Interface Sci. 633, 907\u2013922 (2023).","journal-title":"J. Colloid Interface Sci."},{"key":"60179_CR43","doi-asserted-by":"publisher","first-page":"114266","DOI":"10.1016\/j.ejpb.2024.114266","volume":"198","author":"M Ongun","year":"2024","unstructured":"Ongun, M. et al. Lipid nanoparticles for local delivery of mRNA to the respiratory tract: Effect of PEG-lipid content and administration route. Eur. J. Pharm. Biopharm. 198, 114266 (2024).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"60179_CR44","first-page":"358","volume":"5","author":"P Zhao","year":"2020","unstructured":"Zhao, P. et al. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact. Mater. 5, 358\u2013363 (2020).","journal-title":"Bioact Mater."},{"key":"60179_CR45","doi-asserted-by":"crossref","unstructured":"Lokras, A. G. et al. Cholesterol in mRNA-lipid nanoparticles can be replaced with the synthetic mycobacterial monomycoloyl glycerol analogue MMG-1. Adv. Funct. Mater 35 (2025).","DOI":"10.1002\/adfm.202505627"},{"key":"60179_CR46","doi-asserted-by":"publisher","first-page":"103197","DOI":"10.1016\/j.ebiom.2020.103197","volume":"63","author":"K Worzner","year":"2021","unstructured":"Worzner, K. et al. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. Ebiomedicine 63, 103197 (2021).","journal-title":"Ebiomedicine"},{"key":"60179_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbamem.2005.10.011","volume":"1718","author":"J Davidsen","year":"2005","unstructured":"Davidsen, J. et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6\u2019-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta. 1718, 22\u201331 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"60179_CR48","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3389\/fimmu.2018.02825","volume":"9","author":"A Thakur","year":"2018","unstructured":"Thakur, A. et al. Dual-Isotope SPECT\/CT imaging of the tuberculosis subunit vaccine H56\/CAF01: Induction of strong systemic and mucosal IgA and T-cell responses in mice upon subcutaneous prime and intrapulmonary boost immunization. Front. Immunol. 9, 2825 (2018).","journal-title":"Front. Immunol."},{"key":"60179_CR49","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"Percie du Sert","year":"2020","unstructured":"Percie du Sert. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 18, e3000411 (2020).","journal-title":"PLoS Biol."},{"key":"60179_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nprot.2014.005","volume":"9","author":"KG Anderson","year":"2014","unstructured":"Anderson, K. G. et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc. 9, 209\u2013222 (2014).","journal-title":"Nat. Protoc."},{"key":"60179_CR51","doi-asserted-by":"crossref","unstructured":"Thakur, A. et al. Intrapulmonary (i.pulmon.) pull immunization with the tuberculosis subunit vaccine candidate H56\/CAF01 after intramuscular (i.m.) priming elicits a distinct innate myeloid response and activation of antigen-presenting cells than i.m. or i.pulmon. prime immunization alone. Front. Immunol. 11 (2020).","DOI":"10.3389\/fimmu.2020.00803"},{"key":"60179_CR52","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1021\/acs.molpharmaceut.2c00634","volume":"20","author":"OAO Mullertz","year":"2023","unstructured":"Mullertz, O. A. O., Andersen, P., Christensen, D., Foged, C. & Thakur, A. Pulmonary administration of the liposome-based adjuvant CAF01: Effect of surface charge on mucosal adjuvant function. Mol. Pharm. 20, 953\u2013970 (2023).","journal-title":"Mol. Pharm."},{"key":"60179_CR53","doi-asserted-by":"publisher","first-page":"1427526","DOI":"10.3389\/fimmu.2024.1427526","volume":"15","author":"TS Dutt","year":"2024","unstructured":"Dutt, T. S. et al. ELISA-R: an R-based method for robust ELISA data analysis. Front. Immunol. 15, 1427526 (2024).","journal-title":"Front. Immunol."},{"key":"60179_CR54","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/S2666-5247(22)00337-8","volume":"4","author":"MJ Smit","year":"2023","unstructured":"Smit, M. J. et al. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. Lancet Microbe. 4, e140\u2013e148 (2023).","journal-title":"Lancet Microbe"},{"key":"60179_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","volume":"36","author":"C Lei","year":"2021","unstructured":"Lei, C., Yang, J., Hu, J. & Sun, X. On the calculation of TCID(50) for quantitation of virus infectivity. Virol. Sin. 36, 141\u2013144 (2021).","journal-title":"Virol. Sin"},{"key":"60179_CR56","doi-asserted-by":"publisher","first-page":"104248","DOI":"10.1016\/j.ebiom.2022.104248","volume":"84","author":"D Christensen","year":"2022","unstructured":"Christensen, D. et al. Protection against SARS-CoV-2 transmission by a parenteral prime-intranasal boost vaccine strategy. Ebiomedicine 84, 104248 (2022).","journal-title":"Ebiomedicine"},{"key":"60179_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.1601775","volume":"199","author":"PN Boyaka","year":"2017","unstructured":"Boyaka, P. N. Inducing mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9\u201316 (2017).","journal-title":"J. Immunol."},{"key":"60179_CR58","doi-asserted-by":"publisher","first-page":"e2118312119","DOI":"10.1073\/pnas.2118312119","volume":"119","author":"B Kingstad-Bakke","year":"2022","unstructured":"Kingstad-Bakke, B. et al. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. U. S. A. 119, e2118312119 (2022).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"60179_CR59","doi-asserted-by":"publisher","first-page":"eabq7647","DOI":"10.1126\/sciimmunol.abq7647","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. Sci. Immunol. 7, eabq7647 (2022).","journal-title":"Sci. Immunol."},{"key":"60179_CR60","doi-asserted-by":"crossref","unstructured":"Borrok, M. J. et al. Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies. JCI Insight 3 (2018).","DOI":"10.1172\/jci.insight.97844"},{"key":"60179_CR61","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1038\/s41598-023-32670-w","volume":"13","author":"N Kryukova","year":"2023","unstructured":"Kryukova, N. et al. Mucosal immunity in health care workers\u2019 respiratory tracts in the post-COVID-19 period. Sci. Rep. 13, 7162 (2023).","journal-title":"Sci. Rep."},{"key":"60179_CR62","doi-asserted-by":"publisher","first-page":"23295","DOI":"10.1038\/s41598-024-73004-8","volume":"14","author":"M Itamochi","year":"2024","unstructured":"Itamochi, M. et al. COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naive nursing home residents. Sci. Rep. 14, 23295 (2024).","journal-title":"Sci. Rep."},{"key":"60179_CR63","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-021-24285-4","volume":"12","author":"P Jalkanen","year":"2021","unstructured":"Jalkanen, P. et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. 12, 3991 (2021).","journal-title":"Nat. Commun."},{"key":"60179_CR64","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572\u2013577 (2021).","journal-title":"Nature"},{"key":"60179_CR65","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/22221751.2022.2030199","volume":"11","author":"F Xu","year":"2022","unstructured":"Xu, F. et al. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg. Microbes Infect. 11, 438\u2013441 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"60179_CR66","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1473-3099(23)00350-X","volume":"23","author":"JX Li","year":"2023","unstructured":"Li, J. X. et al. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. Lancet Infect. Dis. 23, 1143\u20131152 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"60179_CR67","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","volume":"8","author":"C Singh","year":"2023","unstructured":"Singh, C. et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin((R))). NPJ Vaccines. 8, 125 (2023).","journal-title":"NPJ Vaccines"},{"key":"60179_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.vetimm.2011.03.004","volume":"148","author":"A Vujanic","year":"2012","unstructured":"Vujanic, A., Sutton, P., Snibson, K. J., Yen, H. H. & Scheerlinck, J. P. Mucosal vaccination: lung versus nose. Vet. Immunol. Immunopathol. 148, 172\u2013177 (2012).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"60179_CR69","doi-asserted-by":"crossref","unstructured":"Sun, L. et al. Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG. Proc. Natl. Acad. Sci. U. S. A. 118 (44) e2107148118 (2021).","DOI":"10.1073\/pnas.2107148118"},{"key":"60179_CR70","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168e114 (2020).","journal-title":"Cell"},{"key":"60179_CR71","doi-asserted-by":"crossref","unstructured":"Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5, eabd2071 (2020).","DOI":"10.1126\/sciimmunol.abd2071"},{"key":"60179_CR72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/infdis\/jiab159","volume":"224","author":"CK Kang","year":"2021","unstructured":"Kang, C. K. et al. Longitudinal analysis of human memory T-cell response according to the severity of Illness up to 8 months after severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 224, 39\u201348 (2021).","journal-title":"J. Infect. Dis."},{"key":"60179_CR73","doi-asserted-by":"publisher","first-page":"eabl5344","DOI":"10.1126\/sciimmunol.abl5344","volume":"6","author":"G Guerrera","year":"2021","unstructured":"Guerrera, G. et al. BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci. Immunol. 6, eabl5344 (2021).","journal-title":"Sci. Immunol."},{"key":"60179_CR74","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","volume":"9","author":"ME Schmidt","year":"2018","unstructured":"Schmidt, M. E. & Varga, S. M. The CD8 T cell response to respiratory virus infections. Front. Immunol. 9, 678 (2018).","journal-title":"Front. Immunol."},{"key":"60179_CR75","doi-asserted-by":"publisher","first-page":"105615","DOI":"10.1016\/j.ebiom.2025.105615","volume":"113","author":"K Worzner","year":"2025","unstructured":"Worzner, K. et al. Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection. Ebiomedicine 113, 105615 (2025).","journal-title":"Ebiomedicine"},{"key":"60179_CR76","unstructured":"Gieger, J., Aneja, K. M. & Rudolph, C. Pulmonary delivery of messenger RNA, US patent application US20150126589A1 (2015)."},{"key":"60179_CR77","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"60179_CR78","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300\u20137306 (2015).","journal-title":"Nano Lett."},{"key":"60179_CR79","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jconrel.2022.11.037","volume":"353","author":"AJ Da Silva Sanchez","year":"2023","unstructured":"Da Silva Sanchez, A. J. et al. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. J. Controlled Release. 353, 270\u2013277 (2023).","journal-title":"J. Control Release"},{"key":"60179_CR80","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"60179_CR81","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.vaccine.2011.10.094","volume":"30","author":"LR Stanberry","year":"2012","unstructured":"Stanberry, L. R. et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 30, 307\u2013316 (2012).","journal-title":"Vaccine"},{"key":"60179_CR82","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41563-022-01404-0","volume":"22","author":"L Rotolo","year":"2023","unstructured":"Rotolo, L. et al. Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung. Nat. Mater. 22, 369\u2013379 (2023).","journal-title":"Nat. Mater."},{"key":"60179_CR83","unstructured":"Ethris. https:\/\/www.ethris.com\/news\/positive-phase-1-clinical-data-of-eth47\/ (2024). Accessed 2\/7-2026."},{"key":"60179_CR84","doi-asserted-by":"publisher","first-page":"e2309748","DOI":"10.1002\/advs.202309748","volume":"11","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency. Adv. Sci. (Weinh). 11, e2309748 (2024).","journal-title":"Adv. Sci. (Weinh)"},{"key":"60179_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jconrel.2016.02.043","volume":"228","author":"M Li","year":"2016","unstructured":"Li, M. et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J. Controlled Release. 228, 9\u201319 (2016).","journal-title":"J. Control Release"},{"key":"60179_CR86","doi-asserted-by":"crossref","unstructured":"Altay Benetti, A. et al. Design and characterization of a new formulation for the delivery of COVID-19-mRNA vaccine to the nasal mucosa. Vaccines (Basel) 12 (2024).","DOI":"10.3390\/vaccines12040409"},{"key":"60179_CR87","doi-asserted-by":"crossref","unstructured":"Zajac, M., Dreano, E., Edwards, A. & Planelles, G. & Sermet-Gaudelus, I. Airway surface liquid pH regulation in airway epithelium current understandings and gaps in knowledge. Int. J. Mol. Sci. 22 (7), 3384 (2021).","DOI":"10.3390\/ijms22073384"},{"key":"60179_CR88","doi-asserted-by":"publisher","first-page":"106370","DOI":"10.1016\/j.ejps.2023.106370","volume":"183","author":"M Massaro","year":"2023","unstructured":"Massaro, M. et al. Lipid nanoparticle-mediated mRNA delivery in lung fibrosis. Eur. J. Pharm. Sci. 183, 106370 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"60179_CR89","doi-asserted-by":"publisher","first-page":"1294929","DOI":"10.3389\/fimmu.2023.1294929","volume":"14","author":"B Clemente","year":"2023","unstructured":"Clemente, B. et al. Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design. Front. Immunol. 14, 1294929 (2023).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60179-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:02:44Z","timestamp":1790902964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60179-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60179"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60179-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"STS is employed by Statens Serum Institut, a non-profit government research facility. CF consults for Lonza and Sanofi. The other authors have no financial conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30629"}}